Skip to main content
Supportive Care, Symptom Management Overview
A Taxing Consequence: Taxane Acute Pain Syndrome
Mark L. Zangardi, PharmD, BCOP
Read More
Original Research
Comparing Oral Chemotherapy Safe Prescribing Practices in an Academic Health System: A Retrospective Analysis
Alison P. Duffy, PharmD, BCOP, Jennifer Cho, PharmD
Read More
FDA Updates
Welcome to the Second Annual Oncology Pharmacy Guide to New FDA Approvals
Read More
FDA Updates
FDA Approvals of Brand-Name Prescription Drugs in 2016
Read More
FDA Updates
Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma
Loretta Fala, Medical Writer
Read More
FDA Updates
Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Tecentriq (Atezolizumab), PD-L1 Inhibitor, Approved for Advanced Bladder Cancer and for Relapsed Non–Small-Cell Lung Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates, Venetoclax
Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
Page 167 of 199
Results 1661 - 1670 of 1986